100726-70-3

Upstream product

• 29203-60-9 2,4-dichloro-N-hydroxybenzenecarboximidoyl chloride 
• 1007476-32-5 sodium ethyl acetylacetate enolate 
• 56843-28-8 2,4-dichlorobenzaldoxime 
• 874-42-0 2,4-dichlorobenzaldeyhde 

Downstream Products

• 4402-78-2 3-(2,4-dichloro-phenyl)-5-methyl-isoxazole-4-carboxylic acid 
• 1610688-75-9 (E)-ethyl 3-(2,4-dichlorophenyl)-5-(2-(dimethylamino)vinyl)isoxazole-4-carboxylate 
• 1610688-82-8 diethyl 5,5'-(4-(dimethylamino)buta-1,3-diene-1,3-diyl)bis(3-(2,4-dichlorophenyl)isoxazole-4-carboxylate) 
• 1610688-90-8 triethyl 5,5',5-(benzene-1,3,5-triyl)tris(3-(2,4-dichlorophenyl)isoxazole-4-carboxylate) 

Relevant academic research and scientific papers

Synthesis and biological activity of ethyl 2-(5-methyl-3-arylisoxazole-4-carboxamido)-4-alkylthiazole-5-carboxylate

A series of novel ethyl 2-(5-methyl-3-arylisoxazole-4-carboxamido)-4-alkylthiazole-5-carboxylates I-1-6 were synthesized. The structures of all target compounds were characterized by 1H NMR, 13C NMR, IR,MS and elemental analyses. Their fungicidal and herbicidal activities were evaluated. The results of preliminary bioassays show that the title compounds I-4 possess 20-50% inhibition against most of the tested plants at the dosage of 150 g ai/ha, while the title compounds I-1-5 possess 32-58% inhibition against FusaHum graminearum, Thanatephorus cucumeris, Botrytis cinereapers and Fusarium oxysporum in vitro at the concentration of 100 mg/L.

IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION

The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.

IL17 AND IFN-GAMMA INHIBITION FOR THE TREATMENT OF AUTOIMMUNE INFLAMMATION

The present invention relates to compounds of the general formula (I), and the pharmaceutically acceptable salt or solvate thereof, as anti-inflammatory and immunomodulatory agents.